Sign in
CompletedNo phase

Coagulation in Acute Aortic Dissection

Key facts

Who runs it
Ivy susanne Modrau, MD
Where
Denmark1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
26 people enrolled
Started
1 Nov 2022
Ended
15 Dec 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Individualized HDR-approach
  • Conventional ACT-approach
Record updated
18 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Age > 18 years
  • Emergent Acute Aortic Dissection with cardiopulmonary bypass
  • Incapable of providing informed consent

Who cannot take part

  • Previous open cardiac surgery
  • History of congenital coagulation disorder (haemophilia)
  • Death during induction of anaesthesia

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Acute aortic dissection (AAD) involving the ascending aorta (Stanford classification type A) remains a life-threatening disease. Excessive perioperative bleeding requiring massive transfusion of allogeneic blood products, and surgical reexploration remain major challenges in these patients. Previous research has indicated that patients with AAD show pronounced haemostatic alterations prior to surgery which are aggravated during major aortic surgery with cardiopulmonary bypass and hypothermia full heparinization.

Read full original descriptionShow less

Intensified anticoagulation management guided by heparin dose response (HDR) calculation, and repeated measurement of heparin concentration may be more effective than standard empiric weight-based heparin and protamine management monitored by activated clotting time (ACT) measurements to suppress thrombin generation during surgery for AAD.

This randomized controlled clinical trial compares the impact of two recommended anticoagulation management strategies during surgery for AAD including deep hypothermia on activation of coagulation: Heparin/protamine-management based on HDR-titration by means of HMS Plus® versus current institutional standard (HDR- versus ACT-approach).

Primary endpoint is thrombin generation as measured by early postoperative prothrombin fragment 1+2 (F1+2). Secondary endpoints are other markers of coagulation and fibrinolysis as well as clinical outcome.

The 2 groups in the trial

  • Individualised HDR-approachExisting treatment, for comparison

    HMS Plus® Hemostasis Management System (Medtronic International, Tolochenaz, CH).

    Treatment: Individualized HDR-approach

  • Conventional ACT-approachExisting treatment, for comparison

    ACT Hemostasis Management

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Anticoagulation Management on Thrombin Generation During Surgery for Acute Aortic Dissection
Publications
Record updated
18 July 2025